青少年和成人丙型肝炎病毒感染筛查:美国预防服务工作组更新证据报告与系统综述
本系统综述更新2013年证据,评估丙型肝炎筛查与直接抗病毒药物(DAA)治疗的获益与危害。无研究直接评估筛查对临床结局的影响;DAA方案汇总持续病毒学应答(SVR)率超过95%,短期严重不良事件率1.9%,且SVR与全因死亡和肝细胞癌风险降低相关。
要点
- DAA方案在各基因型中汇总SVR率超过95%,短期严重不良事件率1.9%。
- 抗病毒治疗后获得SVR与全因死亡风险降低相关(汇总HR 0.40)。
- 获得SVR与肝细胞癌风险降低相关(汇总HR 0.29)。
核心结论
- 直接评估HCV筛查对临床结局影响的证据仍缺乏,但DAA方案SVR率超过95%且短期危害少。
- 抗病毒治疗后获得SVR与全因死亡和肝细胞癌风险降低相关。
研究设计与样本
- 检索Ovid MEDLINE、Cochrane对照试验中心注册库和Cochrane系统综述数据库至2019年2月,监测至2019年9月。
- 由一名研究者提取数据、另一名核查准确性,两名研究者独立评定研究质量。
主要发现
- 无研究评估HCV筛查与不筛查的效果。
- 一项新研究(n=5917)发现基于风险的筛查(灵敏度82%,需筛查15人识别1例HCV)与出生队列筛查(灵敏度76%,需筛查29人)诊断率相似。
- 10项开放标签研究(n=3292)报告DAA治疗后部分生活质量和功能结局有小幅改善(如36项短表健康调查生理和心理成分 summary 量表 less than 3分)。
临床怎么用
- DAA方案在各基因型中SVR率超过95%且短期危害低,支持将其用于HCV感染治疗。
- 抗病毒治疗后获得SVR与全因死亡和肝细胞癌风险降低相关,提示治疗可能改善临床结局。
- 筛查对临床结局的直接效果尚不确定,临床决策需结合其他证据。
局限性
- 无研究直接评估HCV筛查与不筛查对临床结局的影响。
- 抗病毒治疗与肝细胞癌风险的关联在两项队列研究中不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A 2013 review for the US Preventive Services Task Force (USPSTF) of hepatitis C virus (HCV) screening found interferon-based antiviral therapy associated with increased likelihood of sustained virologic response (SVR) and an association between achieving an SVR and improved clinical outcomes. New direct-acting antiviral (DAA) regimens are available. OBJECTIVE: To update the 2013 review on HCV screening to inform the USPSTF. DATA SOURCES: Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews through February 2019, with surveillance through September 2019. STUDY SELECTION: Randomized clinical trials (RCTs) and nonrandomized treatment studies of HCV screening and DAA therapy; cohort studies on screening, antiviral therapy, and the association between an SVR after antiviral therapy and clinical outcomes. DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality. MAIN OUTCOMES AND MEASURES: Mortality, morbidity, quality of life, screening and treatment harms, and screening diagnostic yield. RESULTS: Eight RCTs of DAA therapy vs placebo or an outdated antiviral regimen, 48 other treatment studies, and 33 cohort studies, with a total of 179 230 participants, were included. No study evaluated effects of HCV screening vs no screening. One new study since the 2013 review (n = 5917) found similar diagnostic yield of risk-based screening (sensitivity, 82%; number needed to screen to identify 1 HCV case, 15) and birth cohort screening (sensitivity, 76%; number needed to screen, 29), assuming perfect implementation. Ten open-label studies (n = 3292) reported small improvements in some quality-of-life and functional outcomes (eg, less than 3 points on the 0 to 100 36-Item Short Form Health Survey physical and mental component summary scales) after DAA treatment compared with before treatment. Two cohort studies (n = 24 686) found inconsistent associations of antiviral therapy vs no therapy with risk of hepatocellular carcinoma. Forty-nine treatment studies (n = 10 181) found DAA regimens associated with pooled SVR rates greater than 95% across genotypes, and low short-term rates of serious adverse events (1.9%) and withdrawal due to adverse events (0.4%). An SVR after antiviral therapy was associated with decreased adjusted risk of all-cause mortality (13 studies, n = 36 986; pooled hazard ratio [HR], 0.40 [95% CI, 0.28-0.56) and hepatocellular carcinoma (20 studies, n = 84 491; pooled HR, 0.29 [95% CI, 0.23 to 0.38]) vs no SVR. CONCLUSIONS AND RELEVANCE: Direct evidence on the effects of HCV screening on clinical outcomes remains unavailable, but DAA regimens were associated with SVR rates greater than 5% and few short-term harms relative to older antiviral therapies. An SVR after antiviral therapy was associated with improved clinical outcomes compared with no SVR.
引用
- Chou R, Dana T, Fu R, et al. Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020. PMID: 32119034. doi:10.1001/jama.2019.20788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。